A review is given on some of the more recent knowledge of the enzymes involved in the control of glycosphingolipids biosynthesis and how catabolic deficiency leads to the glycosphingolipidoses. Focus is on how small-molecule inhibitors have been instrumental in probing the enzymes in these pathways and how their application has been taken from discovery in the laboratory to therapeutic use in man.
No takes yet. Share an insight, caveat, or question.
Butters et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: